Copenhagen, January 5, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin announces today an agreement granting exclusive rights to Actor Pharmaceuticals Pty Ltd, to commercialize MC2’s Wynzora® Cream for the treatment of plaque psoriasis for adults in Australia. Wynzora® Cream was approved by The Australian Government Department of Health and Aged Care (Therapeutic Goods Administration) November 11, 2024, for topical treatment of mild to moderate plaque psoriasis on the body in adults and for treatment of scalp psoriasis.
“Actor Pharmaceuticals is an Australian pharmaceutical company marketing innovative and branded pharmaceutical products. With Actor’s expertise, ambition and strategy to develop a meaningful dermatology portfolio, Actor is an excellent partner for MC2 to bring Wynzora® to Australian patients” said Trine Ahlgreen, Chief Executive Officer of MC2 Therapeutics. “This partnership supports our mission to make Wynzora® available to as many patients suffering from plaque psoriasis as possible.”
“We look forward to working with MC2 to make Wynzora® Cream available to Australians who suffer from plaque psoriasis,” said Mark Jaggers, Chief Commercial Officer of Actor Pharmaceuticals. “Wynzora® Cream’s unique formulation and clinical profile will offer patients a new treatment option designed for effect and satisfaction in daily routines. Feedback from other countries where Wynzora® has been launched gives us confidence that Wynzora will also be welcomed by Australian patients.”
About Wynzora® Cream
Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment for plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology™, allowing an effective convenient-to-use aqueous formulation. Wynzora® Cream was approved in the US by the FDA on July 20th, 2020, and in the first country in Europe on July 9th, 2021.
About MC2 Therapeutics A/S
MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin through innovative and effective therapies. The company is dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support.
Wynzora® Cream is partnered with leading pharmaceutical companies specializing in dermatology covering more than 40 countries in four continents. The company is based in Hørsholm, Denmark and in Guildford, United Kingdom. For additional information on MC2 Therapeutics, please visit https://www.mc2therapeutics.com
Contact:
Trine Ahlgreen, +45 3150 5036, info@mc2therapeutics.com
About Actor Pharmaceuticals PTY, LTD.
Actor Pharmaceuticals., headquartered in Sydney, Australia, is a specialty pharmaceutical company focused on providing best-in-class pharmaceuticals, biosimilar medicines and over-the-counter products to healthcare professionals and consumers on the Australian and New Zealand market. For more information, visit www.actorpharma.com.au/
BACK
